Pemirolast ophthalmic - Santen
Alternative Names: Alamast; Alegysal; BMY 26517; DE 068; Pemilaston; Pemirolast ophthalmic; Pemirolast potassiumLatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation
- Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Allergic conjunctivitis; Seasonal allergic rhinitis
Most Recent Events
- 07 Mar 2011 Mitsubishi Tanabe Pharma Corporation transfers marketing rights of Alegysal® to its subsidiary, Tanabe Seiyaku Hanbai
- 24 May 2004 Launched for Allergic conjunctivitis in China (Ophthalmic)
- 24 May 2004 Launched for Allergic conjunctivitis in Philippines (Ophthalmic)